Natco Pharma Ltd (NATCOPHARM) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Natco Pharma achieved its highest ever consolidated revenue and profits in FY24-25.
- Consolidated total revenue reached INR 4,784 crores, a 16% YoY growth.
- Net profit for the year surged by 36% YoY to INR 1,883.4 crores.
- Q4 FY25 consolidated revenue stood at INR 1,287.3 crores, with a net profit of INR 406 crores.
- The company maintains a strong cash position of over INR 3,500 crores.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.